Search
Foxy-5
go.drugbank.com/drugs/DB13034InvestigationalFoxy-5 has been used in trials studying the treatment of Prostate Cancer, Colorectal Cancer, Metastatic Colon Cancer, Metastatic Breast Cancer, and Metastatic Prostate Cancer.
Molgramostim
go.drugbank.com/drugs/DB12525InvestigationalMolgramostim has been used in trials studying the treatment of Bronchiectasis, Cystic Fibrosis, Pulmonary Alveolar Proteinosis, Acute Respiratory Distress Syndrome, and Autoimmune Pulmonary Alveolar Proteinosis
AFN-1252
go.drugbank.com/drugs/DB12658InvestigationalAFN-1252 has been used in trials studying the treatment of Cellulitis, Burn Infection, Wound Infection, Cutaneous Abscess, and Skin and Subcutaneous Tissue Bacterial Infections.
Anti-CD19 CAR-T cells
go.drugbank.com/drugs/DB21913InvestigationalCD19 CAR-T is under investigation in clinical trial NCT05618041 (The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients with Hematological Malignancies).
Zamubafusp alfa
go.drugbank.com/drugs/DB32269InvestigationalZamubafusp alfa is an immunoglobulin-peptide fusion protein.[L55038] It consists of a humanized IgG1 and p5R which is a pan-amyloid reactive peptide.[L55038]
UDP-alpha-D-xylose
go.drugbank.com/drugs/DB01713ExperimentalThe decarboxylation product of UDPglucuronic acid, which is used for formation of the xylosides of seryl hydroxyl groups in mucoprotein synthesis. Also forms plant xylans.
7,8-dihydrobiopterin
go.drugbank.com/drugs/DB04400Experimental7,8-Dihydrobiopterin is an inhibitor of the enzyme dihydroneopterin aldolase (DHNA), which catalyzes the conversion of 7,8-Dihydrobiopterin to 6-hydroxymethyl-7,8-dihydropterin and glycolaldehyde.
Hycanthone
go.drugbank.com/drugs/DB14061ExperimentalHycanthone was approved by the FDA in 1975 but is no longer used.
Nemtabrutinib
go.drugbank.com/drugs/DB18866InvestigationalNemtabrutinib is under investigation in clinical trial NCT05624554 (A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/small Lymphocytic
IMCY-0141
go.drugbank.com/drugs/DB17019InvestigationalIMCY-0141 is a synthetic peptide based on MOG (Myelin Oligodendrocyte Glycoprotein), a dominant autoantigen, designed to stop the progression of multiple sclerosis (MS) and the destruction of the myelin